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Introduction. Several studies demonstrated that anti-inﬂammatory remedies exhibit excellent anti-neoplastic properties. An
extract of Pluchea odorata (Asteraceae), which is used for wound healing and against inﬂammatory conditions, was fractionated
and properties correlating to anti-neoplastic and wound healing eﬀects were separated. Methods. Up to six fractionation steps
using silica gel, Sephadex columns, and distinct solvent systems were used, and eluted fractions were analysed by thin layer
chromatography, apoptosis, and proliferation assays. The expression of oncogenes and proteins regulating cell migration was
investigated by immunoblotting after treating HL60 cells with the most active fractions. Results. Sequential fractionations enriched
anti-neoplastic activities which suppressed oncogene expression of JunB, c-Jun, c-Myc, and Stat3. Furthermore, a fraction (F4.6.3)
inducing or keeping up expression of the mobility markers MYPT, ROCK1, and paxillin could be separated from another fraction
(F4.3.7), which inhibited these markers. Conclusions. Wound healing builds up scar or speciﬁc tissue, and hence, compounds
enhancing cell migration support this process. In contrast, successful anti-neoplastic therapy combats tumour progression, and
thus, suppression of cell migration is mandatory.
1.Introduction
Drug discovery is a constant need for biomedical research
and clinical progress. Particularly mega-biodiversity areas
such as the tropical rainforests of Central America are very
promising for the discovery of new pharmaceutical lead
compounds. Therefore, we chose an ethnomedical approach
todrugdiscoveryandfocussedontraditionalremediesofthe
Maya to preselect plants with proven health eﬀects.
Traditional medicine plants are often used for hundreds
of years [1], which is the reason why no or only little
toxic eﬀects in humans can be expected. Especially in Africa
and Central and South America, traditional medicine is
advised by shamans, curanderos, or herbalists who often
keep the use of the healing plants as a secret [2]. Although
these plants are used since ages, little is known about the
“pinciples of activity” and/or the targeted cellular mech-
anisms, and hence, these remedies have a great potential2 Evidence-Based Complementary and Alternative Medicine
for drug development. We aimed for the separation and
isolation of distinct properties of the Maya healing plant
Pluchea odorata which are relevant for anticancer treatment.
P. odorata grows in the USA, Mexico, Belize, Guatemala,
Panama,CaymanIslands,Guadeloupe,Jamaica,PuertoRico,
St. Lucia, Venezuela, and Ecuador (Germplasm Resources
Information Network, United States Department of Agri-
culture, 9 November 2004, http://www.ars-grin.gov/cgi-bin/
npgs/html/taxon.pl?104497) and is still used by the Maya to
treat common cold, fever, ﬂu, head colds, headache, hyper-
tension,neuralgia,ophthalmia,palsy,pneumonia,snakebite,
swellings, inﬂammation, and bruises of the skin [3]. The
medicalsolutionispreparedbyboilingtwohandfulsofleaves
inonegallonofwater,andthenitisfrequentlyappliedonthe
aﬀectedareauntiltheinﬂammationsubsides[4].Furtherthe
plant is described as being antidote, astringent, diaphoretic,
and haemostatic [5], as well as traditionally used by mothers
after giving birth to decrease the risk for infections and
conveyance of tissue recovery [3]. Gridling et al. [6]a n d
Bauer et al. [7] describe a strong anti-neoplastic eﬀect of the
dichloromethane extract in HL60 and MCF-7 cells and an
anti-inﬂammatory response in HUVECs (human umbilical
vein endothelial cells).
Pharmaceutical drugs are prepared under standardised
conditions and usually contain just one active principle. In
contrast, ethnopharmacologic remedies are mixtures of a
vast number of compounds, which are in many cases un-
known,andvaryintheircompositionandactivitydepending
on the growth area and the time of collection. This makes
them diﬃcult for application and trading. Moreover, plant
extracts can also contain compounds that are systemically
toxic or counteract the desired eﬀect of the active princi-
ple(s). On the other hand, some of the diﬀerent compounds
in a plant extract can synergise. The present work will
give examples of this phenomenon. A common reason to
terminate ap r i o r isuccessful therapies of all kinds of cancer
and other diseases is the acquisition of drug resistance.
However, it has not been reported so far that complex plant
mixturesinducetreatmentresistancesinpatients,mostlikely
because several distinct active principles target various intra-
and intercellular signalling pathways simultaneously thereby
preventing that the organism develops an “escape mecha-
nism.” Thus, the development of complex extracts should
be considered as a strategy to treat cancer. Standardisation
proceduresforsuchmixturesmustbeindividuallydeveloped
to provide therapeutics which are eﬀective and safe and
do not exhibit batch to batch variations. The fractionation
and accompanying testing in bioassays and by appropriate
analyses are a feasible concept for standardisation and
remedies emerging along such procedures can be approved
by national agencies (i.e., Avemar, WO 2004014406 (A1):
“Useofafermentedwheatgermextractasanti-inﬂammatory
agent” by Hidvegi and Resetar).
Here we describe a fractionation approach of the dichlo-
romethane extract of P. odorata, which was constantly con-
trolled regarding its activity by bio-assays and analyses
that can be standardised. This resulted in fractions causing
distinct cellular responses indicative for wound healing or
anti-neoplastic properties.
2.MaterialandMethods
2.1. Plant Material. The aerial parts (leaves, caulis, ﬂore-
scence) of Pluchea odorata (L.) Cass. were collected in
Guatemala, Departamento Pet´ en, near the north-western
shore of Lago Pet´ en Itz´ a, San Jos´ e, within an area of
four-year-old secondary vegetation ∼1km north of the
road from San Jos´ et oL aN u e v aS a nJ o s ´ e( 1 6 ◦59
 30
   N,
89◦54
 00
   W). Voucher specimens (leg. G. Krupitza & R.
O. Frisch, Nr. 1-2009, 08. 04. 2009, Herbarium W) were
archived at the Museum of Natural History, Vienna, Austria.
6kg of air-dried plant material has been extracted with
dichloromethane by Bj¨ orn Feistel (Finzelberg GmbH & Co.
K G ,A n d e r n a c h ,G e r m a n y ) ,a n dt h ee x t r a c ts t o r e di na n
exsiccator in the dark at 4◦C until use.
2.2. Plant Extraction and Fractionation. Plant extraction
with dichloromethane was essentially as described earlier
[6, 7]. 6000g dried plant material was extracted with dichlo-
romethane resulting in 220g dry extract (extraction was
performed by Finzelberg GmbH & Co. KG, Andernach,
Germany).
Vacuum Liquid Chromatography (VLC) was used for the
separation of large amounts of extract. 36g dichloromethane
extract was redissolved in dichloromethane, mixed with 70g
silica gel and evaporated to dryness, and ground in a mortar
to obtain a homogenous powder. A 12 × 40cm column was
packed with 900g silica gel, on top the silica gel-containing
extract, and covered with sea sand to ballast the sample. The
mobile phase was passed through by application of reduced
pressure.After checking the collectedfractions by TLC,those
with similar bands were recombined, and this resulted in
three combined fractions (F1.1–F1.3; Table 1).
VLCFractionationofF1.1.10gofF1.1,whichwasderiv ed
from the crude extract, was dissolved in dichloromethane,
mixed with 20g silica gel, evaporated to dryness, reﬁned in a
mortar, and applied on top of a 5 × 60cm silica gel column.
Compounds were eluted with the mobile phases shown in
Table 2 by applying reduced pressure. Collected fractions
were checked by TLC, and similar fractions were recombined
yielding nine combined fractions (F2.1–F2.9).
Column Chromatography (CC) Fractionation of F2.6
(Less Than 2g of Residue was fractionated by CC). 1.6g
F2.6,whichwasgainedbyfractionationofF1.1wasdissolved
in dichloromethane, mixed with 3g silica gel, evaporated to
dryness, placed on top of a 5 × 50cm silicia gel column and
eluted with mobile phases shown in Table 3. The collected
fractions were checked by TLC and those with similar band
patterns were recombined to yield ten combined fractions
(F3.1–F3.10).
CC Fractionation of F3.3. 1.08g of F3.3, which was
derived from F2.6, was dissolved in dichloromethane and
p l a c e do nt o po fa2× 30cm silica gel column. Mobile phases
were used as illustrated in Table 4. Fractions were checked by
TLC, and those with similar band patterns were recombined
yielding twelve combined fractions (F4.3.1–F4.3.12).
CC Fractionation of F4.3.7. 146mg F4.3.7 was dissolved
dichloromethane and applied on a 80 × 1.5cm silica gel
column and fractionated with one litre solvent (chloroform:Evidence-Based Complementary and Alternative Medicine 3
Table 1: Mobile phases used for VLC of the dichloromethane extract.
Mobile phase Relation Volume (l) Fractions Residue (g)
Petroleum ether 4
Petroleum ether:chloroform 9:1 5 F1.1 23.9
Chloroform 12
Chloroform:methanol 9:1 9 F1.2 10.8g
Chloroform:methanol 7:3 9
Chloroform:methanol 5:5 9
Chloroform:methanol 3:7 9 F1.3 1.6g
Chloroform:methanol 1:9 9
Methanol 9
Table 2: Mobile phases used for VLC of F1.1.
Mobile phase Relation Volume (l) Fractions Residue (g)
Dichloromethane:hexan 8:2 2 F2.1 1.63
Dichloromethane 2 F2.2 0.17
Dichloromethane:ethyl acetate 8:2 1 F2.3 1.28
Dichloromethane:ethyl acetate 6:4 1 F2.4
Dichloromethane:ethyl acetate 4:6 1 F2.5 4.57
Dichloromethane:ethyl acetate 2:8 1 F2.6 1.73
Ethyl acetate 1 F2.7 0.22
Ethyl acetate:methanol 8:2 1 F2.8 0.04
Ethyl acetate:methanol 6:4 1 F2.9 0.12
Table 3: Mobile phases used for CC of F2.6.
Mobile phase Relation Volume (l) Fractions Residue (g)
Dichloromethane 100% 1 F3.1 0.02
Dichloromethane:ethyl acetate 80:20 2 F3.2 0.05
F3.3 1.14
Dichloromethane:ethyl acetate 60:40 1 F3.4 0.07
F3.5 0.05
Dichloromethane:ethyl acetate 40:60 1 F3.6 0.32
F3.7 0.02
Dichloromethane:ethyl acetate 20:80 1 F3.8 0.01
F3.9 0.03
Ethyl acetate 100% 1 F3.10 0.04
Table 4: Mobile phases used for CC of F3.3.
Mobile phase Relation Volume (mL) Fractions Residue (mg)
Dichloromethane 100% 500 F4.3.1 0.4
Dichloromethane:ethyl acetate 90:10 500
F4.3.2 3
F4.3.3 59
F4.3.4 91
Dichloromethane:ethyl acetate 80:20 500 F4.3.5 256
F4.3.6 65
Dichloromethane:ethyl acetate 60:40 500 F4.3.7 146
F4.3.8 8
Dichloromethane:ethyl acetate 40:60 500 F4.3.9 6
F4.3.10 111
Dichloromethane:ethyl acetate 20:80 500 F4.3.11 63
Ethyl acetate 100% 500 F4.3.12 34 Evidence-Based Complementary and Alternative Medicine
Table 5: Stationary phase, mobile phases, and detection methods
used for TLC.
Stationary
phase Silica gel plates 60 F254 (Merck, Darmstadt, Germany)
Mobile
phase
TLC system 1:chloroform:methanol:water 90:22:3.5
TLC system 2:chloroform:methanol:water
90:3.5:0.2
TLC system 3:dichloromethane:ethyl acetate 80:20
TLC system 4:dichloromethane:ethyl acetate 85:15
TLC system 5:chloroform:methanol:water 70:22:3.5
Detection UV254,UV365, visible light
Anisaldehyde sulphuric acid reagent (ASR)
methanol: water, 95:1.5:0.1). Fractions were collected in
tubes, ten drops per minute, and every 30 minutes the
tubeswerechanged.Afterwardsthecolumnwaswashedwith
300mL methanol. Fractions were checked by TLC, and those
with similar band patterns were recombined resulting in
twelve fractions (F5.3.7.1–F5.3.7.12; see Figure 3(c)).
CC Fractionation of F3.6. 0.32g F3.6, which was derived
from F2.6, was dissolved in methanol and applied on top
of a 3.5 × 40cm Sephadex column (2.5 × 40cm for 3.6).
Methanol was used as mobile phase, and fractions were
collected and checked by TLC, and those with similar band
patterns were recombined to yield four combined fractions:
F4.6.1(9mg),F4.6.2(5mg),F4.6.3(207mg),F4.6.4(55mg).
CC Fractionation of F4.6.3. 20mg F4.6.3 (very oily),
which was derived from F3.6, was dissolved in dichloro-
methane, mixed with silica gel, and applied on top a
2.5 × 15cm dichloromethane conditioned silica gel col-
umn. Successful elution was achieved with dichlorome-
thane:ethylacetate (50:50). Fractions were checked by
TLC and those with similar band patterns were recom-
bined yielding six combined fractions (F5.6.3.1–F5.6.3.6; see
Figure 4(b)).
2.3. Thin Layer Chromatography (TLC). TLC was used for
control of fractionation. Stationary phase and mobile phases
are described in Table 5. The mobile phase varied between
ﬁve solvent systems. Plates were detected under UV254,
UV366, and visible light, before and after spraying with
anisaldehyde sulphuric acid reagent (ASR). ASR consisted
of 0.5mL anisaldehyde, 10mL glacial acetic acid, 85mL
methanol and 5mL H2SO4 (sulfuric acid). The sprayed plate
was heated at 100◦C for ﬁve minutes, and then compounds
were detected under UV254,365 and visible light. Unless
otherwise stated 8μL extract or fraction solution was applied
to the plate.
2.4. Cell Culture. HL-60 (human promyelocytic leukaemia
cell) cells were purchased from American Type Culture
Collection (ATCC). The cells were grown in RPMI 1640
mediumwhichwassupplementedwith10%heat-inactivated
fetal calf serum (FCS), 1% Glutamax, and 1% Penicillin-
Streptomycin.Bothmediumandsupplementswereobtained
from Life Technologies (Carlsbad, CA, USA). The cells were
kept in humidiﬁed atmosphere at 37◦C containing 5% CO2.
2.5. Proliferation Assay. Proliferation assays [8, 9]w e r e
performed to analyse the inhibition of proliferation of HL-
6 0c e l l st r e a t e dwi t he x t r a c to rf r a c t i o n so fP. odorata.E x t r a c t
and fractions were dissolved in ethanol (ﬁnal concentration
was 0.2%). HL-60 cells were seeded in 24-well plates at
a concentration of 1 × 105 cells per mL RPMI medium
allowing logarithmic growth within the time of treatment
with plant extract or fractions. The control was treated
with solvent. After 24 and 48 hours, the number of cells
was determined using the Sysmex Cell Counter (Sysmex
Corp., Kobe, Japan). Experiments were done in triplicate.
Percentage of cell division progression compared to the
untreated control was calculated by applying the following
formula:
C48 or 72h +d rug−C24h +d rug
C48 or 72h −drug −C24h +d rug
× 100 = % cell division.
(1)
2.6. Apoptosis Assay. Determination of cell death by Hoechst
33258 (HO) and propidium iodide (PI) double staining
(both Sigma, St. Louis, MO, USA) allows identifying the
amount and the type of cell death (early or late apoptosis
or necrosis) [10–12]. Therefore, HL-60 cells were seeded in
a 24-well plate at a concentration of 1 × 105 cells per mL
RPMI medium. Cells were treated with fractions or extract
of P. odorata. The cells were incubated for 8, 24, 48, and/or
72 hours, depending on the experiment. At each time point,
100μL cell suspension of each well was transferred into
separate wells of a 96-well plate, and Hoechst 33285 and pro-
pidium iodide were added at ﬁnal concentrations of 5μg/mL
and 2μg/mL, respectively. After one hour of incubation at
37◦C, stained cells were examined and photographed with
an Axiovert ﬂuorescence microscope (Zeiss, Jena, Germany)
equipped with a DAPI ﬁlter. Type and number of cell deaths
were evaluated by visual examination of the photographs
according to the morphological characteristics revealed by
HOPI staining. Experiments were done in triplicate.
2.7. Western Blotting. Preparation of lysates. HL60 cells were
seeded in a tissue culture ﬂask at a concentration of 1 ×
106 cells per mL RPMI medium. P. odorata fractions F1,
F4.6.3, and F4.3.7 were analysed by western blots. HL60 cells
were either incubated with 40μg/mL F1 or with 10μg/mL of
one of the other two P. odorata fractions for the indicated
times. At each time point, 4 × 106 cells were harvested,
placed on ice, and centrifuged (1000rpm, 4◦C, 4min). Then,
the supernatant (medium) was discarded, and the pellet
was washed twice with cold phosphate buﬀered saline (PBS,
pH 7.2) and centrifuged (1000rpm, 4◦C, 4min). The cell
pellet was lysed in a buﬀer containing 150mM NaCl, 50mM
Tris (pH 8.0), 1% Triton-X-100, 1mM phenylmethylsulfonyl
ﬂuoride(PMSF),and1mMproteaseinhibitorcocktail(PIC)
(Sigma, Schnelldorf, Germany). Afterwards the lysate was
centrifuged at 12000rpm for 20min at 4◦C. Supernatant
was transferred into a 1.5mL tube and stored at −20◦Cf o r
further analyses.
Gel electrophoresis (SDS-PAGE) and blotting. Equal
amountsofproteinsamples(lysate)weremixedwithsodiumEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: Antiproliferative eﬀect of (a) dichloromethane crude extract, (b) fraction F1.1 in HL60 cells; 1 × 105 cells/mL were seeded into
24-well plate, incubated with 5, 15, and 40μg/mL extract or fraction F1.1, and the percentage of proliferation was calculated relative to
solvent treated control within a 24h period, (c) Induction of apoptosis by F1.1: cells were grown as described and incubated with 15 and
40μg/mL of each fraction for 72h. Then, cells were double stained with Hoechst 33258 and propidium iodide and examined under the
microscope with UV light connected to a DAPI ﬁlter. Nuclei with morphological changes which indicated cell death were counted, and the
percentages of dead cells were calculated. Experiments were performed in triplicate. Asterisks indicate signiﬁcance compared to untreated
control (P<0.05), and error bars indicate ±SD. (d) 1 × 106 cells/mL were incubated with 40μg / m LF 1 . 1a n dh a rv e s t e da f t e r0 . 5 ,2 ,4 ,8 ,a n d
24h of treatment, lysed, and total protein applied to SDS-PAGE. Western blot analysis was conducted with the indicated antibodies. Equal
sample loading was conﬁrmed by Ponceau S staining and β-actin analysis.
dodecyl sulfate (SDS) sample buﬀer (1:1) and loaded
onto a 10% polyacrylamide gel. Proteins were separated
by polyacrylamide gel electrophoresis (PAGE) at 120 Volt
for approximately one hour. To make proteins accessible
to antibody detection, they were electrotransferred from
the gel onto a polyvinylidene diﬂuoride (PVDF) Hybond
membrane (Amersham, Buckinghamshire, UK) at 95 Volt
for 80 minutes. Membranes were allowed to dry for 30
minutes to provide ﬁxing of the proteins on the membrane.
Methanol was used to moist the membranes. Equal sample
loadingwascheckedbystainingthemembranewithPonceau
S (Sigma, Schnelldorf, Germany).6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: (a) Induction of apoptosis of HL60 cells by F2.1–F2.9. 1 × 105 cells/mL were seeded in 24-well plates and incubated with 10μg/mL
of each fraction for 72h. Then, cells were double stained with Hoechst 33258 and propidium iodide and examined under the microscope
with UV light connected to a DAPI ﬁlter. Nuclei with morphological changes which indicated cell death were counted, and the percentages
of dead cells were calculated. Signiﬁcance was calculated in comparison to control (Co). (b) Antiproliferative eﬀect of F3.3 and F3.6: 1 × 105
cells/mL were seeded into 24-well plate, incubated with 2 and 10μg/mL of each fraction, and the percentage of proliferation was calculated
relative to solvent treated control within a 24h period. Experiments were performed in triplicate. Asterisks indicate signiﬁcance compared
to untreated control (P<0.05) and error bars indicate ±SD. (c) Thin layer chromatography (TLC) of F2.6 and F3.1–F3.10; Mobile phase:
TLC system 2. Detection: visible light with ASR.
Protein detection. After washing with PBS or TBS (Tris
buﬀered saline, pH 7.6), membranes were blocked in PBS-
or TBS-milk (5% nonfat dry milk in PBS containing 0.5%
Tween 20 or TBS containing 0.1% Tween 20) for one
hour at room temperature. Then membranes were washed
with PBS/T (PBS containing 0.5% Tween 20) or TBS/T
(TBS containing 0.1% Tween 20), changing the washing
solution four to ﬁve times every ﬁve minutes. Then every
membrane was incubated with a primary antibody (1:500)
in blocking solution (according to the data sheet TBS-,
PBS-milk or TBS-, PBS-BSA), at 4◦C over night gently
shaking. Subsequently the membrane was again washed with
PBS/T or TBS/T and incubated with the second antibody
(peroxidase-conjugated goat anti-rabbit IgG or anti-mouse
IgG)diluted1:2000foronehouratroomtemperature.After
washing the membranes, chemiluminescence was developed
with enhanced chemiluminescence (ECL) plus detection
kit (Amersham, UK) (two seconds to ten minutes), and
membraneswereexposedtotheLumi-ImagerF1(Roche)for
increasing times.
2.8. Antibodies. Monoclonal mouse ascites ﬂuid anti-acet-
ylated α-tubulin (6-11B-1) and β actin (AC-15) antibod-
ies were from Sigma (St. Louis, MO, USA). Monoclonal
mouse α-tubulin (DM1A), β-tubulin (H-235), Cdc25A
(F-6), and polyclonal rabbit paxillin (H-114), ROCK-1
(C8F7), c-Jun (H-79), Jun b (210) were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Monoclonal
rabbit cleaved caspase 8 (Asp391) (18C8) and phospho-
Stat3 (Tyr705)(D3A7) antibodies and polyclonal rabbit
cleaved caspase 3 (Asp175), human-speciﬁc cleaved caspase
9 (Asp330), phospho-Chk2 (Thr68), Chk2, phospho-myosin
light chain 2 (MLC2-Ser19), myosin light chain 2, Stat3,
and MYPT1 were from Cell Signaling (Danvers, MA, USA).
Polyclonal rabbit phospho-Cdc25A (Ser177) antibody was
from Abgent (San Diego, CA, USA), polyclonal rabbitEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: (a) Antiproliferative eﬀect of F4.3.1–F4.3.12 in HL60 cells; 1 × 105 cells/mL were seeded into 24-well plates, incubated with 5
and 10μg/mL of each fraction, and the percentage of proliferation was calculated relative to solvent treated control within a 24h period. (b)
Induction of apoptosis by F4.3.7 and (c) by F5.3.7.1–F5.3.7.12 in HL60 cells; 1 × 105 cells/mL were seeded in 24-well plates and incubated
with (b) 5 and 10μg/mL of F4.3.7 for 24 and 48h and (c) with 2 and 5μg/mL of each indicated fraction for 24h. Then, cells were double
stained with Hoechst 33258 and propidium iodide and examined under the microscope with UV light connected to a DAPI ﬁlter. Nuclei
with morphological changes which indicated cell death were counted, and the percentages of dead cells were calculated. Experiments were
performed in triplicate. Asterisks indicate signiﬁcance compared to untreated control (P<0.05), and error bars indicate ±SD.
phospho-MYPT1 (Thr696) from Upstate (NY, USA), mouse
monoclonal γH2AX (pSer139) (DR 1017) from Calbiochem
(San Diego, CA, USA), and mouse monoclonal c-Myc Ab-2
(9E10.3) from Thermo Fisher Scientiﬁc, Inc. (Fremont, CA,
USA).Thesecondaryantibodiesperoxidase-conjugatedanti-
rabbit IgG and anti-mouse IgG were purchased from Dako
(Glostrup, Denmark).
2.9. Statistical Analysis. For statistical analyses, Excel 2003
software and Prism 5 software package (GraphPad, San
D i e g o ,C A ,U S A )w e r eu s e d .T h ev a l u e sw e r ee x p r e s s e d
as mean ± standard deviation, and Student’s t-test was
applied to compare diﬀerences between control samples and
treatment groups. Statistical signiﬁcance level was set to P<
0.05.
3. Results and Discussion
The dichloromethane extract of P. odorata exhibits strong
anti-neoplastic activity (Figure 1(a)). Therefore, we fraction-
ated this extract and constantly monitored the activities by
bio-assays measuring apoptosis and/or proliferation rates to8 Evidence-Based Complementary and Alternative Medicine
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Figure 4:(a)Inductionofapoptosis;1 ×105 HL60cells/mLwereseededin24-wellplatesandincubatedwith2and/or10μg/mLofF4.6.3for
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compared to untreated control (P<0.05), and error bars indicate ±SD.
get closer to the active principles. In the ﬁrst round the
crude extract was split in three distinct fractions of which
fraction F1.1 exhibited the strongest anti-proliferative and
proapoptotic activity (Figures 1(b) and 1(c)). 40μg F1.1/mL
inducedcaspase3anddecreasedβ-actinandα-tubulinlevels,
and therefore also reduced acetylation levels of α-tubulin
were detected within 4h of treatment (Figure 1(d)). This
suggested that the overall protein decrease was due to the
early activation of caspase 3 and subsequent cell death.
F1.1 was further processed yielding fractions F2.1–F2.9.
F2.6 was nearly as active F2.7 (Figure 2(a)) but contained
∼10 times more fraction material (1.9g versus 0.2g, resp.).
Therefore, F2.6 was further processed yielding fractions
F3.1–F3.10 (Figures 2(b) and 2(c)).
10μg/mLofF3.4–F3.6exhibitedpotentanti-proliferative
properties in HL60 cells suppressing cell growth by 100%.
The TLC analysis showed that both, F3.3 and F3.6, contained
a distinct main compound, and therefore F3.3 and F3.6 were
further fractionated. Also F3.2 was processed, however, this
yielded only several low-activity fractions (data not shown).
(i) The subfractionation of F3.3 on a silica gel column
yielded the potent antiproliferative and proapoptotic
fraction F4.3.7 (Figures 3(a) and 3(b)). Further
fractionation of F4.3.7 caused the decomposition of
the strong cytotoxic activity into many low active
fractions (F5.3.7.1–F5.3.7.12; Figure 3(c)), which in
sum approximated the activity of the precursor.
(ii) The subprocessing of F3.6 yielded fractions F4.6.1–
F4.6.4. F4.6.3, which was very oily, was the most
pro-apoptotic one (Figure 4(a)). Upon further frac-
tionation, the activity of F4.6.3 also decomposed
into several low-activity fractions (F5.6.3.1–F5.6.3.6;
Figure 4(b)).
Therefore, we went back to F4.3.7 and F4.6.3 and
continued analyses with these two distinct high-activity
fractions. The TLC patterns of F4.3.7 and F4.6.3 were clearly
diﬀerent from each other evidencing that they contain
diﬀerent compounds (Figure 5(a)). To characterise the two
distinct fraction types, posttranslational modiﬁcations and
expression levels of proteins, which are relevant for apop-
tosis and cell cycle arrest, were investigated. F4.3.7 slightly
induced Chk2 phosphorylation and hence its activation,
whereas F4.6.3 did not (Figure 5(b)). Chk2 was shown to
phosphorylate Cdc25A at Ser177 and tags it for proteasomal
degradation [13, 14]. However, treatment of HL60 cells with
F4.3.7 caused the dephosphorylation of Ser177 and protein
stabilisation. Also F4.6.3 stabilised Cdc25A despite Ser177
phosphorylation. This implicated that Cdc25A was not
regulatedbyChk2activityinthisscenario.MoreoverCdc25A
stabilisation suggested an increase in cell cycle activity [15].
Nevertheless, cell proliferation was inhibited.
In search of molecular causes for reduced proliferation,
we found that the fractionation steps enriched a spindle
toxin or an indirect microﬁlament-targeting activity. This
was reﬂected by induced α-tubulin acetylation, which is an
indicator of the polymerisation status of tubulin microﬁl-
aments [16, 17], within 2h of treatment with F4.3.7 and
F4.6.3 (Figure 5(c)). Thereafter, caspase 3 became activated.
Also the phosphorylation of H2AX occurred after treatmentEvidence-Based Complementary and Alternative Medicine 9
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Figure 5:(a)Thinlayerchromatography(TLC)ofF4.6.3(leftpanel)andF4.3.7(rightpanel);mobilephase:TLCsystem2;detection:UV254.
Analysis of (b) cell cycle and checkpoint regulators, (c) apoptosis-related proteins, (d) oncogenes, (e) proteins required for mobility; 1 ×
106 HL60 cells/mL were incubated with 10μg/mL F4.6.3 and F4.3.7, respectively, and harvested after 0.5, 2, 4, 8, and 24h of treatment. Cells
were lysed and obtained proteins samples applied to SDS-PAGE. Western blot analysis was performed with the indicated antibodies. Equal
sample loading was conﬁrmed by Ponceau S staining β-actin or β-tubulin analysis.10 Evidence-Based Complementary and Alternative Medicine
with both fractions indicating DNA damage presumably due
to caspase-3-induced DNase activity of DNA fragmentation
factor (DFF; [18]), because caspase 3 activation and H2AX
phosphorylation appeared simultaneously [19]. Evidently,
the molecular onset of apoptosis occurred faster than the
orchestrated expression of the investigated cell cycle regu-
lators. Interestingly, the activation of caspase 3 concurred
with the activation of caspase 8, but not with activation of
caspase 9, indicating that the extrinsic apoptosis pathway
became activated and not the intrinsic one. The signature-
type processing of caspase 3 into the active fragment was
more prominent by F1.1 than by F4.3.7 and F4.6.3. This was
most likely due to the four times higher F1.1 concentration
used (40μg/mL), which caused also the degradation of α-
tubulin and β-actin as consequence of swift onset of cell
death.
The low or absent activation of Chk2 (resp.) suggested
that a genotoxic activity, which was formerly present in
the crude extract [6] and in other subfractions [7], was
eliminated throughout the described fractionations. Avoid-
ing genotoxicity can be beneﬁcial, because it reduces DNA
damage and subsequent mutations that may cause sec-
ondary malignancies. Cdc25A, a classiﬁed oncogene [20,
21] was upregulated by both fraction types and therefore
we investigated also the expression of other oncogenes,
which are related to tumour growth and progression. F4.6.3
had a substantial eﬀect on the repression of c-Myc and
only a minor eﬀect on c-Jun. Even more eﬀective F4.3.7
suppressed also the phosphorylation of Tyr705 of Stat3 and
thus inhibited its function, which is known to play a role
in tumour progression [22]. This fraction further repressed
JunB, c-Jun, and c-Myc more eﬀectively than F4.6.3.
Since P. odorata is used also as a wound healing remedy,
this property also involves tissue regeneration and the
regulation of a process called “epithelial to mesenchymal
transition” (EMT) [23, 24]. The most prominent feature
of EMT is the acquisition of a mobile phenotype [25, 26].
If transient and tightly regulated, EMT is beneﬁcial for
the organism, because it contributes to acute inﬂammation
and tissue repair [27–29]. In contrast, the chronic status
occurrence of EMT causes pathologies such as progression
of cancer [30]. The mobility of cancer cells is a prerequisite
for the intra- and extravasation of the vasculature, tissue
invasion,andmetastaticspread[23,31],anditismediatedby
proteins that allow cell plasticity and movement. Therefore,
the alteration of motility-related gene products in cancerous
cells, such as paxillin [32, 33], ROCK1 [34], MLC2 for the
formation of stress ﬁbres [35] and MYPT [36], are indicators
for increased mobility and hence cancer progression. Also
leukaemia cells such as diﬀerentiated HL60 attach to the
ECM and vascular cells and transmigrate through vessel
walls, invade tissues [37–39], and add to the progression
of the disease. Hence, HL60 cells possess a repertoire of
proteins facilitating cell movement although they normally
grow in suspension. Treatment with F4.3.7 caused ROCK1
repression below constitutive and detectable levels, which
was not the case with F4.6.3 (Figure 5(d)). Also MYPT
expression decreased upon treatment with F4.3.7. Paxillin
became upregulated by F4.6.3 treatment and marginally by
F4.3.7, and this was also the case for the phosphorylation of
MLC2.SinceP. odorata issuccessfullyusedfortissuerecovery
and healing of skin bruises, the increased mobility of cells
(ﬁbroblasts, epithelial cells, macrophages, etc.) is required to
close the tissue disruption. This very property, however, is
detrimentalthroughoutcancertreatment,andeliminationof
this activity might be beneﬁcial for this purpose. Therefore,
future research has to address the question whether F4.3.7
is advantageous for cancer cell treatment, whereas F4.6.3
exhibits advanced wound healing properties.
4. Conclusions
A spindle-damaging activity became enriched by fractiona-
tions, which was reﬂected by increased α-tubulin acetylation
followed by the activation of caspases 8 and 3 and the typical
nuclear morphology of apoptosis. The impact on apoptosis
and the orchestration of apoptosis regulator activation were
similar for both fractions. In comparison to earlier work,
genotoxic components activating Chk2 were eliminated.
Importantly, F4.6.3 induced mobility markers, whereas
F4.3.7 inhibited the expression of mobility markers or
did not interfere with their constitutive expression. This
property implicates an inhibitory eﬀect of F4.3.7 on tumour
progression which was also reﬂected by the downregulation
of the Jun family of oncogenes and the suppression of Stat3
activity.
Theseﬁndingscanprovideabasisforthedevelopmentof
remedies (1) supporting wound healing in case of F4.6.3 or
(2) interfering with tumour progression in case of F4.3.7.
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